1-2 of 2
Michel Van Gelder, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Arnon P. Kater, MD, Marinus H.J. H.J. Van Oers, MD PhD, Yvette Norden, Roberto D. Liu, Martin R. Schipperus, Martine Chamuleau, MD PhD, Marcel Nijland, MD, Jeanette K. Doorduijn, MD PhD, Michel van Gelder, MDPhD, Mels Hoogendoorn, MDPhD, Fransien Croon-de Boer, Shulamit Wittebol, Martijn Kerst, MDPhD, Willem Marijt, Ward Posthuma, MD PhD, Reinier Raymakers, MDPhD, Ron Schaafsma, MDPhD, Johan Dobber, Sabina Kersting, MDPhD, Mark-David Levin
Journal: Blood
Blood (2017) 130 (Supplement 1): 4328.
https://doi.org/10.1182/blood.V130.Suppl_1.4328.4328
Published: 2017
Journal Articles

Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

Bart W. Schot, MD, JoseĢe Zijlstra, MD, Otto S. Hoekstra, MDPhD, Jan Pruim, MDPhD, Gustaaf W. van Imhoff, MD, Wim Sluiter, PhD, John M.M. Raemaekers, MDPhD, Wim Oyen, MDPhD, Michel Van Gelder, MDPhD, Olga Eriks, PhD, P.C. Huijgens, MDPhD, Edo Vellenga, MDPhD
Journal: Blood
Blood (2006) 108 (11): 2400.
https://doi.org/10.1182/blood.V108.11.2400.2400
Published: 2006